NASDAQ:TELO Telomir Pharmaceuticals Q4 2024 Earnings Results & Report $1.04 -0.05 (-4.59%) As of 09:49 AM Eastern This is a fair market value price provided by Massive. Learn more. Telomir Pharmaceuticals missed analyst earnings expectations in its Q4 2024 results, released February 4, 2025. The company reported EPS of -$0.10 versus the -$0.05 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateFebruary 4, 2025TimeAfter Market Closes Telomir Pharmaceuticals EPS ResultsActual EPS-$0.10Consensus EPS -$0.05Beat/MissMissed by -$0.05One Year Ago EPSN/AEPS Beat Rate4 of last 7 quartersTelomir Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsTelomir Pharmaceuticals' next earnings date is estimated for Wednesday, December 2, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Telomir Pharmaceuticals Q4 2024 Earnings FAQ Did Telomir Pharmaceuticals beat earnings estimates for Q4 2024? Telomir Pharmaceuticals (NASDAQ:TELO) reported earnings of -$0.10 per share for Q4 2024, missing the consensus estimate of -$0.05. The report was announced on Tuesday, February 4, 2025. When is Telomir Pharmaceuticals' next earnings date? Telomir Pharmaceuticals' next earnings date is estimated for Wednesday, December 2, 2026. MarketBeat tracks confirmed and estimated earnings dates for Telomir Pharmaceuticals on the company's earnings history page. Telomir Pharmaceuticals Earnings HeadlinesTelomir Pharmaceuticals, Inc. announced that it has received $5.618228 million in fundingOctober 6, 2026 | marketscreener.comMTelomir (NASDAQ: TELO) secures $5.6 million PIPE as DeJoria adds capitalOctober 6, 2026 | americanbankingnews.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.October 15 at 1:00 AM | Stansberry Research (Ad)Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the CompanyOctober 6, 2026 | globenewswire.comResearch shows Telomir-Zn might slow bone cancer in dogsSeptember 24, 2026 | msn.comMaxim Initiates Telomir Pharmaceuticals at Buy With $4 Price TargetSeptember 18, 2026 | marketscreener.comMSee More Telomir Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Telomir Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Telomir Pharmaceuticals and other key companies, straight to your email. Email Address About Telomir PharmaceuticalsTelomir Pharmaceuticals (NASDAQ:TELO) is a clinical-stage biotechnology company focused on developing treatments for age-related diseases and conditions associated with cellular aging. The company’s research centers on telomeres, protective structures at the ends of chromosomes that generally shorten as cells divide and age. Telomir’s lead investigational product is Telomir-1, a proprietary small-molecule compound designed to promote telomere lengthening and support cellular function. The company is evaluating its potential application in diseases associated with aging, including osteoarthritis and other conditions involving tissue degeneration. Telomir-1 remains an investigational therapy and is not an approved drug. Telomir Pharmaceuticals is pursuing preclinical and clinical development activities intended to establish the safety and effectiveness of its technology. As a development-stage biotechnology company, its primary activities include drug discovery, research collaborations, and advancing Telomir-1 toward potential regulatory approval rather than marketing commercial products.View Telomir Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling?UnitedHealth Beats on Earnings, But Investors Question Growth PathIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
